carnitine has been researched along with Coronary Heart Disease in 116 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-Carnitine is abundant in animal source foods, particularly red meat, and circulating L-carnitine may be related to the incidence of coronary heart disease (CHD)." | 8.12 | Ten-year changes in plasma L-carnitine levels and risk of coronary heart disease. ( DiDonato, JA; Heianza, Y; Hu, FB; Ma, W; Manson, JE; Qi, L; Rexrode, KM; Rimm, EB; Sun, Q, 2022) |
| "To investigate the potential influence on one analogue of carnitine on the electrophysiologic derangements elicited by myocardial ischemia and subsequent reperfusion, we evaluated whether increasing concentrations of propionylcarnitine would interact with carnitine acyltransferase I and thereby decrease the accumulation of long-chain acylcarnitines during hypoxia in isolated adult canine myocytes." | 7.68 | Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium. ( Corr, PB; Dobmeyer, DJ; Kanter, EM; Priori, SG; Yamada, KA, 1991) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 7.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "Effects of L-carnitine on ventricular arrhythmias and myocardial metabolism in a reperfused ischemic myocardium were studied in 35 anesthetized mongrel dogs." | 7.66 | Effects of L-carnitine on ventricular arrhythmias after coronary reperfusion. ( Abe, M; Hayashi, H; Kamikawa, T; Kobayashi, A; Masumura, Y; Nishihara, K; Suzuki, Y; Yamazaki, N, 1983) |
| "L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane." | 6.36 | Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983) |
| "Infusions of DL-carnitine are reported to improve the tolerance to atrial pacing of patients with angina pectoris." | 5.05 | Intravenous dl-carnitine fails to increase the double-product during atrial pacing in patients with effort angina. A double-blind randomized study. ( Biagini, A; Carpeggiani, C; Maseri, A; Mazzei, MG; Opie, L; Rovai, D, 1983) |
| "L-Carnitine is abundant in animal source foods, particularly red meat, and circulating L-carnitine may be related to the incidence of coronary heart disease (CHD)." | 4.12 | Ten-year changes in plasma L-carnitine levels and risk of coronary heart disease. ( DiDonato, JA; Heianza, Y; Hu, FB; Ma, W; Manson, JE; Qi, L; Rexrode, KM; Rimm, EB; Sun, Q, 2022) |
| "Our data suggest three possible clinically actionable endotypes in primary OA: muscle weakness, arginine deficit and low inflammatory OA." | 4.02 | Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. ( Furey, A; Liu, M; Rahman, P; Randell, EW; Sun, G; Werdyani, S; Zhai, G; Zhang, H, 2021) |
| "To investigate the potential influence on one analogue of carnitine on the electrophysiologic derangements elicited by myocardial ischemia and subsequent reperfusion, we evaluated whether increasing concentrations of propionylcarnitine would interact with carnitine acyltransferase I and thereby decrease the accumulation of long-chain acylcarnitines during hypoxia in isolated adult canine myocytes." | 3.68 | Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium. ( Corr, PB; Dobmeyer, DJ; Kanter, EM; Priori, SG; Yamada, KA, 1991) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 3.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "Though the efficacies of procainamide and disopyramide in treating arrhythmias are well established, their precise mechanisms of antiarrhythmic action remain unclear." | 3.67 | Effects of procainamide and disopyramide on long chain acyl carnitine and long chain acyl CoA concentrations in the ischemic heart. ( Kobayashi, A; Watanabe, H; Yamazaki, N, 1988) |
| "Effects of L-carnitine on ventricular arrhythmias and myocardial metabolism in a reperfused ischemic myocardium were studied in 35 anesthetized mongrel dogs." | 3.66 | Effects of L-carnitine on ventricular arrhythmias after coronary reperfusion. ( Abe, M; Hayashi, H; Kamikawa, T; Kobayashi, A; Masumura, Y; Nishihara, K; Suzuki, Y; Yamazaki, N, 1983) |
| "L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane." | 2.36 | Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983) |
| "Carnitine kinetics were investigated in 28 normotensive patients with significant left coronary artery disease, during and after incremental atrial pacing." | 1.30 | Acute myocardial ischaemia induces cardiac carnitine release in man. ( Bartels, GL; Remme, WJ; Scholte, HR, 1997) |
| "L-Carnitine is a key regulatory compound of glucose and fatty acid metabolism in the myocardium." | 1.30 | [The effect of L-carnitine on ischemic heart disease: experimental results]. ( Lerch, R, 1998) |
| " Long-term administration of L-carnitine increases the cardiac L-carnitine content in mice and has been shown to improve surrogate markers of coronary heart disease such as arrhythmias, nitrate consumption, and left ventricular dilatation and infarct size in patients after myocardial infarction." | 1.30 | [Physiologic bases for the use of L-carnitine in cardiology]. ( Krähenbühl, S, 1998) |
| "Carnitine can cause overall improvement in cardiac performance in patients with CAD as well as in cardiomyopathy." | 1.30 | L-carnitine administration in coronary artery disease and cardiomyopathy. ( Aslam, M; Singh, RB, 1998) |
| "In L-propionylcarnitine-treated pigs, cardiac output remained at 75% of baseline, and systemic vascular resistance decreased from 42 +/- 3 to 38 +/- 4 mmHg." | 1.28 | L-propionylcarnitine increases postischemic blood flow but does not affect recovery of energy charge. ( Bezstarosti, K; Lamers, JM; Sassen, LM; Van der Giessen, WJ; Verdouw, PD, 1991) |
| "Carnitine itself was ineffective." | 1.28 | Protective effects of propionyl-L-carnitine during ischemia and reperfusion. ( Paulson, D; Regitz, V; Shug, A; Subramanian, R, 1991) |
| "3." | 1.28 | Effect of D,L-carnitine on the response of the isolated heart of the rat to ischaemia and reperfusion: relation to mitochondrial function. ( Duan, JM; Karmazyn, M, 1989) |
| "L-carnitine treatment to diabetic rats significantly reduced serum glucose, FFA, triglycerides, and ketones." | 1.27 | Improvement of myocardial function in diabetic rats after treatment with L-carnitine. ( Paulson, DJ; Ramacci, MT; Schmidt, MJ; Shug, AL; Traxler, JS, 1984) |
| "Pretreatment of L-carnitine prevented the decrease in free carnitine and ATP and the increase in long-chain acyl carnitine and long-chain acyl CoA." | 1.27 | Effects of L-carnitine on tissue levels of free fatty acid, acyl CoA, and acylcarnitine in ischemic heart. ( Kamikawa, T; Kobayashi, A; Suzuki, Y; Yamazaki, N, 1983) |
| "L-carnitine-pretreatment prevented the reduction of these phospholipids." | 1.27 | Effects of L-carnitine on phospholipids in the ischemic myocardium. ( Kobayashi, A; Nagao, B; Yamazaki, N, 1987) |
| "L-Propionylcarnitine was the most protective agent." | 1.27 | Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. ( Noonan, J; Paulson, DJ; Schmidt, M; Shug, AL; Traxler, J, 1986) |
| "Carnitine has therapeutic potential for the postischemic heart by facilitating the oxidation of acylated fatty acid metabolites, the intracellular accumulation of which has a deleterious effect on myocardial function and metabolism." | 1.27 | Effect of carnitine on myocardial function and metabolism following global ischemia. ( Feinberg, H; Levitsky, S; Schmitt, G; Silverman, NA; Vishwanath, M, 1985) |
| "dl-Carnitine treatments in nine hearts, not supplemented with extra FFA were without apparent effect in improving overall hemodynamic performance." | 1.26 | Effects of carnitine in ischemic and fatty acid supplemented swine hearts. ( Liedtke, AJ; Nellis, SH, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 89 (76.72) | 18.7374 |
| 1990's | 24 (20.69) | 18.2507 |
| 2000's | 1 (0.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (1.72) | 2.80 |
| Authors | Studies |
|---|---|
| Woster, PM | 1 |
| Murray, WJ | 1 |
| Heianza, Y | 1 |
| Ma, W | 1 |
| DiDonato, JA | 1 |
| Sun, Q | 1 |
| Rimm, EB | 1 |
| Hu, FB | 1 |
| Rexrode, KM | 1 |
| Manson, JE | 1 |
| Qi, L | 1 |
| Werdyani, S | 1 |
| Liu, M | 1 |
| Zhang, H | 1 |
| Sun, G | 1 |
| Furey, A | 1 |
| Randell, EW | 1 |
| Rahman, P | 1 |
| Zhai, G | 1 |
| Celik, T | 1 |
| Kursaklioglu, H | 1 |
| Iyisoy, A | 1 |
| Jata, B | 1 |
| Corr, PB | 8 |
| Gross, RW | 3 |
| Sobel, BE | 7 |
| Hu, ZW | 1 |
| Siliprandi, N | 2 |
| Di Lisa, F | 2 |
| Toninello, A | 1 |
| Bowe, C | 1 |
| Nzonzi, J | 1 |
| Corsin, A | 1 |
| Moravec, J | 1 |
| Feuvray, D | 8 |
| Lamers, JM | 4 |
| Stinis, HT | 1 |
| Montfoort, A | 1 |
| Hülsmann, WC | 4 |
| Rebouche, CJ | 2 |
| Engel, AG | 1 |
| Kobayashi, A | 7 |
| Kamiya, J | 2 |
| Yamashita, T | 1 |
| Ishizaka, K | 1 |
| Hayashi, H | 2 |
| Kamikawa, T | 5 |
| Yamazaki, N | 8 |
| Leblond, Y | 1 |
| Kudo, Y | 1 |
| Shoji, T | 2 |
| Oimatsu, H | 1 |
| Yoshida, S | 2 |
| Kikuchi, K | 1 |
| Iimura, O | 2 |
| Watarai, I | 1 |
| Chien, KR | 1 |
| Sen, A | 1 |
| Buja, LM | 1 |
| Willerson, JT | 1 |
| Biagini, A | 1 |
| Opie, L | 1 |
| Rovai, D | 1 |
| Mazzei, MG | 1 |
| Carpeggiani, C | 1 |
| Maseri, A | 1 |
| Paulson, DJ | 4 |
| Schmidt, MJ | 1 |
| Traxler, JS | 1 |
| Ramacci, MT | 2 |
| Shug, AL | 12 |
| Moore, KH | 1 |
| Koen, AE | 1 |
| Hull, FE | 1 |
| Suzuki, Y | 4 |
| Masumura, Y | 2 |
| Nishihara, K | 1 |
| Abe, M | 1 |
| Ichihara, K | 1 |
| Robishaw, JD | 1 |
| Vary, TC | 3 |
| Neely, JR | 6 |
| Lee, BI | 1 |
| Reibel, DK | 1 |
| Sugiyama, S | 2 |
| Miyazaki, Y | 2 |
| Kotaka, K | 2 |
| Ozawa, T | 2 |
| Liedtke, AJ | 4 |
| Nellis, SH | 5 |
| Fultz, CW | 1 |
| Ogawa, K | 1 |
| Satake, T | 1 |
| Plouët, J | 1 |
| Whitesell, LF | 1 |
| Snyder, DW | 1 |
| Cain, ME | 1 |
| Crafford, WA | 1 |
| Schiavoni, G | 1 |
| Lucente, M | 1 |
| Di Folca, A | 1 |
| Alessandri, N | 1 |
| Mongiardo, R | 1 |
| Manzoli, U | 1 |
| Gilmour, RF | 1 |
| Williams, ES | 1 |
| Farmer, BB | 1 |
| Zipes, DP | 1 |
| Bartels, GL | 3 |
| Remme, WJ | 3 |
| Pillay, M | 2 |
| Schönfeld, DH | 2 |
| Kruijssen, DA | 1 |
| Rizzon, P | 4 |
| Iliceto, S | 1 |
| Marangelli, V | 1 |
| Scholte, HR | 1 |
| Brevetti, G | 1 |
| Fanin, M | 1 |
| De Amicis, V | 1 |
| Carrozzo, R | 1 |
| Di Lello, F | 1 |
| Martone, VD | 1 |
| Angelini, C | 1 |
| Lerch, R | 1 |
| Krähenbühl, S | 1 |
| Singh, RB | 1 |
| Aslam, M | 1 |
| Thomsen, JH | 2 |
| Yap, VU | 1 |
| Patel, AK | 1 |
| Karras, TJ | 1 |
| DeFelice, SL | 1 |
| Idell-Wenger, JA | 2 |
| Grotyohann, LW | 1 |
| Pitts, BJ | 1 |
| Tate, CA | 1 |
| Van Winkle, WB | 1 |
| Wood, JM | 3 |
| Entman, ML | 2 |
| Broquist, HP | 1 |
| Borum, PR | 1 |
| Opie, LH | 1 |
| Sinclair-Smith, BC | 1 |
| Folts, JD | 3 |
| Bittar, N | 3 |
| Klein, MI | 1 |
| Koke, JR | 3 |
| Huth, PJ | 1 |
| Hanley, HG | 1 |
| Hartley, CJ | 1 |
| Swain, JA | 1 |
| Busch, U | 1 |
| Chang, CH | 1 |
| Lewis, RM | 2 |
| Morgan, WJ | 1 |
| Schwartz, A | 2 |
| Chen, SH | 1 |
| Lincoln, SD | 1 |
| Cox, PH | 1 |
| Kruijssen, HA | 1 |
| Knufman, NM | 1 |
| Fernandez, C | 1 |
| Proto, C | 1 |
| Lagioia, R | 1 |
| Scrutinio, D | 2 |
| Mangini, SG | 1 |
| Ricci, A | 2 |
| Mastropasqua, F | 1 |
| Valentini, G | 2 |
| Ramunni, G | 1 |
| Totaro Fila, G | 1 |
| Schneijdenberg, CT | 1 |
| Verkleij, AJ | 1 |
| Leipälä, JA | 1 |
| Bhatnagar, R | 1 |
| Pineda, E | 1 |
| Najibi, S | 1 |
| Massoumi, K | 1 |
| Packer, L | 1 |
| Fujiwara, M | 1 |
| Nakano, T | 1 |
| Tamoto, S | 1 |
| Yamada, Y | 1 |
| Fukai, M | 1 |
| Takada, K | 1 |
| Ashida, H | 1 |
| Shimada, T | 1 |
| Ishihara, T | 1 |
| Seki, I | 1 |
| Sassen, LM | 1 |
| Bezstarosti, K | 1 |
| Van der Giessen, WJ | 1 |
| Verdouw, PD | 2 |
| Chiddo, A | 2 |
| Gaglione, A | 1 |
| Musci, S | 1 |
| Troito, G | 1 |
| Grimaldi, N | 1 |
| Locuratolo, N | 1 |
| Ferrari, R | 2 |
| Ceconi, C | 1 |
| Cargnoni, A | 1 |
| Pasini, E | 1 |
| Boffa, GM | 1 |
| Curello, S | 1 |
| Visioli, O | 2 |
| Shug, A | 1 |
| Paulson, D | 1 |
| Subramanian, R | 2 |
| Regitz, V | 5 |
| Yamada, KA | 2 |
| Dobmeyer, DJ | 1 |
| Kanter, EM | 1 |
| Priori, SG | 1 |
| DaTorre, SD | 1 |
| Creer, MH | 2 |
| Pogwizd, SM | 1 |
| Demeyere, R | 2 |
| Lormans, P | 2 |
| Weidler, B | 1 |
| Minten, J | 1 |
| Van Aken, H | 2 |
| Flameng, W | 2 |
| Okamoto, M | 1 |
| Tojo, H | 1 |
| Mock, T | 1 |
| Man, RY | 1 |
| Fleck, E | 4 |
| Duan, JM | 1 |
| Karmazyn, M | 1 |
| Bressler, R | 1 |
| Gay, R | 1 |
| Copeland, JG | 1 |
| Bahl, JJ | 1 |
| Bedotto, J | 1 |
| Goldman, S | 1 |
| Caiati, C | 1 |
| Galantino, A | 1 |
| Piper, HM | 1 |
| Das, A | 1 |
| Saffitz, JE | 2 |
| Agnoletti, G | 1 |
| Ciampalini, G | 1 |
| Albertini, A | 1 |
| Böhles, H | 1 |
| Pauly, DF | 1 |
| Yoon, SB | 1 |
| McMillin, JB | 1 |
| Lopaschuk, GD | 1 |
| Wall, SR | 1 |
| Olley, PM | 1 |
| Davies, NJ | 1 |
| Watanabe, H | 1 |
| Schüler, S | 2 |
| Yankah, C | 1 |
| Hetzer, R | 2 |
| Goa, KL | 1 |
| Brogden, RN | 1 |
| van der Vusse, GJ | 1 |
| Prinzen, FW | 1 |
| van Bilsen, M | 1 |
| Engels, W | 1 |
| Reneman, RS | 1 |
| Müller, M | 1 |
| Yankah, CA | 1 |
| Pivetta, A | 1 |
| Miotto, G | 1 |
| Siliprandi, D | 1 |
| Molaparast-Saless, F | 2 |
| Liedkte, AJ | 1 |
| Plehn, S | 1 |
| Noonan, J | 3 |
| Schmidt, M | 2 |
| Nadeau, A | 1 |
| Tancrède, G | 1 |
| Rousseau-Migneron, S | 1 |
| Pacifici, L | 1 |
| Botarelli, M | 1 |
| Cantagallo, A | 1 |
| Maccari, F | 2 |
| Angelucci, L | 1 |
| Theisen, K | 1 |
| Nagao, B | 1 |
| De Jonge-Stinis, JT | 1 |
| Simkhovich, BZ | 1 |
| Vitolinia, RO | 1 |
| Stivrinia, MI | 1 |
| Shutenko, ZhV | 1 |
| Meĭrena, DV | 1 |
| Bentham, JM | 1 |
| Higgins, AJ | 1 |
| Woodward, B | 1 |
| Hekimian, G | 1 |
| Fazekas, T | 1 |
| Csáti, S | 1 |
| Selmeczi, A | 1 |
| Udvary, E | 1 |
| Szekeres, L | 1 |
| Traxler, J | 1 |
| Dubelaar, ML | 1 |
| Sato, R | 1 |
| Nohara, K | 1 |
| Kudoh, Y | 1 |
| Ishiyama, N | 1 |
| Motoe, M | 1 |
| Silverman, NA | 1 |
| Schmitt, G | 1 |
| Vishwanath, M | 1 |
| Feinberg, H | 1 |
| Levitsky, S | 1 |
| Zhao, ZQ | 1 |
| Wang, RX | 1 |
| Wu, BW | 1 |
| Zhao, RR | 1 |
| Shipp, JC | 1 |
| Menahan, LA | 1 |
| Crass, MF | 1 |
| Chaudhuri, SN | 1 |
| Sordahl, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes[NCT00351234] | 200 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
16 reviews available for carnitine and Coronary Heart Disease
| Article | Year |
|---|---|
Amphipathic metabolites and membrane dysfunction in ischemic myocardium.
Topics: Acyl Coenzyme A; Animals; Carnitine; Cell Membrane; Coronary Disease; Electrophysiology; Fatty Acids | 1984 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
[Metabolism of long chain fatty acids in the normal and pathologic heart: effects of ischemia].
Topics: Acyl Coenzyme A; Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus; Dogs; Fatty Ac | 1984 |
Metabolic products and myocardial ischemia.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Circulation; Coronary Disease; Dogs; Energy Metabolism | 1981 |
Control of energy metabolism of heart muscle.
Topics: Adenine Nucleotides; Animals; Carnitine; Coenzyme A; Coronary Disease; Energy Metabolism; Fatty Acid | 1981 |
Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
Topics: Acetanilides; Carnitine; Clinical Trials as Topic; Coenzymes; Coronary Disease; Enzyme Inhibitors; H | 1995 |
[Consensus conference on the therapeutic effects of L-carnitine in patients with myocardial ischemia and left ventricular remodeling].
Topics: Carnitine; Coronary Disease; Humans; Myocardial Infarction; Myocardial Ischemia; Ventricular Functio | 1998 |
[L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review].
Topics: Angina Pectoris; Carnitine; Chronic Disease; Coronary Disease; Drug Evaluation; Germany; Humans; Ita | 1992 |
Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Electrophysiology; Humans; Lipid Metabol | 1991 |
[Heart failure in dilated cardiomyopathy and coronary heart disease. The contribution of biochemical parameters to assessing the prognosis].
Topics: Cardiomyopathy, Dilated; Carnitine; Catecholamines; Coronary Disease; Glucose; Heart Failure; Humans | 1988 |
l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.
Topics: Carnitine; Coronary Disease; Fatty Acids; Humans | 1987 |
Accumulation of lipids and lipid-intermediates in the heart during ischaemia.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Fatty Acids, Nonesterified; Glycerophosphates | 1987 |
Lysophospholipids, long chain acylcarnitines and membrane dysfunction in the ischaemic heart.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Fatty Acids; Lysophospholipids; Myocardi | 1987 |
Transport and function of L-carnitine and L-propionylcarnitine: relevance to some cardiomyopathies and cardiac ischemia.
Topics: Animals; Biological Transport; Cardiomyopathies; Carnitine; Coronary Disease; Humans; Myocardium; Sa | 1987 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Heart triglycerides in health and disease.
Topics: Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus; Fatty Acids, Nonesterified; Gly | 1973 |
9 trials available for carnitine and Coronary Heart Disease
| Article | Year |
|---|---|
Intravenous dl-carnitine fails to increase the double-product during atrial pacing in patients with effort angina. A double-blind randomized study.
Topics: Angina Pectoris; Cardiac Pacing, Artificial; Carnitine; Coronary Disease; Hemodynamics; Humans; Male | 1983 |
Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris.
Topics: Aged; Angina Pectoris; Cardiac Output; Cardiotonic Agents; Carnitine; Coronary Disease; Electrocardi | 1994 |
Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine.
Topics: Carnitine; Conditioning, Psychological; Coronary Disease; Exercise; Glycogen; Humans; Male; Middle A | 1997 |
[L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review].
Topics: Angina Pectoris; Carnitine; Chronic Disease; Coronary Disease; Drug Evaluation; Germany; Humans; Ita | 1992 |
Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Carnitine; Coronary Disease; Double-Blind Method; Exer | 1992 |
[Effect of L-carnitine in patients with ischemic heart disease].
Topics: Adult; Aged; Carnitine; Catecholamines; Coronary Circulation; Coronary Disease; Energy Metabolism; E | 1991 |
Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Carnitine; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Energy Metabolism; F | 1990 |
Cardioprotective effects of carnitine in extensive aorto-coronary bypass grafting.
Topics: Adenosine Triphosphate; Carnitine; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; He | 1989 |
[Acute effects of propionyl-L-carnitine on anomalies of parietal kinetics of the left ventricle induced by atrial pacing in patients with ischemic heart disease. A bidimensional echocardiographic study].
Topics: Adult; Cardiac Pacing, Artificial; Carnitine; Coronary Disease; Double-Blind Method; Echocardiograph | 1989 |
92 other studies available for carnitine and Coronary Heart Disease
| Article | Year |
|---|---|
Synthesis and biological evaluation of cyclic analogues of 1-carnitine as potential agents in the treatment of myocardial ischemia.
Topics: Animals; Carnitine; Carnitine Acyltransferases; Coronary Disease; Mitochondria, Heart; Rats; Transfe | 1986 |
Ten-year changes in plasma L-carnitine levels and risk of coronary heart disease.
Topics: Animals; Carnitine; Case-Control Studies; Coronary Disease; Female; Prospective Studies; Red Meat; R | 2022 |
Endotypes of primary osteoarthritis identified by plasma metabolomics analysis.
Topics: Aged; Arginine; Body Mass Index; Carnitine; Case-Control Studies; Coronary Disease; Diabetes Mellitu | 2021 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Carnitine; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme I | 2008 |
[Abnormalities of myocardial lipid metabolism and advances of drug intervention in acute myocardial ischemia].
Topics: Adrenergic beta-Antagonists; Animals; Carnitine; Coronary Disease; Fatty Acids; Fatty Acids, Noneste | 1984 |
Biochemical derangements in ischemic myocardium: the role of carnitine.
Topics: Acyl Coenzyme A; Acyltransferases; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Carni | 1984 |
Lipid intermediates in chronically volume-overloaded rat hearts. Effect of diffuse ischemia.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Cardiomegaly; Carnitine; Coenzyme A; Coronary Dise | 1984 |
The effect of lipid intermediates on Ca2+ and Na+ permeability and (Na+ + K+)-ATPase of cardiac sarcolemma. A possible role in myocardial ischemia.
Topics: Animals; Calcimycin; Calcium; Carnitine; Cell Membrane Permeability; Coronary Disease; Fatty Acids; | 1984 |
Effects of glucose-insulin-potassium solution on free fatty acid metabolism in ischemic myocardium.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Dogs; Fatty Acids, No | 1984 |
[Study on the risk factors of ischemic heart disease in patients with chronic hemodialysis, with special reference to the role of plasma l-carnitine].
Topics: Adult; Carnitine; Coronary Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Regressi | 1983 |
Fatty acylcarnitine accumulation and membrane injury in ischemic canine myocardium.
Topics: Animals; Calcium; Carnitine; Coronary Disease; Dogs; Endocardium; Fatty Acids; Female; Male; Myocard | 1983 |
Improvement of myocardial function in diabetic rats after treatment with L-carnitine.
Topics: Animals; Blood Glucose; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus, Experimental; Fa | 1984 |
beta-Hydroxy fatty acid production by ischemic rabbit heart.
Topics: Animals; Carnitine; Coenzyme A; Coronary Disease; Fatty Acids, Nonesterified; Hydroxy Acids; Male; R | 1982 |
Arrhythmogenic properties of phospholipid metabolites associated with myocardial ischemia.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Electrophysiology; Glycerophosphates; He | 1983 |
Effects of L-carnitine on ventricular arrhythmias after coronary reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Coronary Vessels; Dogs; Ligation; Myocar | 1983 |
Ultrastructural, functional, and metabolic correlates in the ischemic rat heart. Effects of free fatty acid.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Glucose; Male; Mitochondria, Heart; Palmitic | 1983 |
Effects of L-carnitine on tissue levels of free fatty acid, acyl CoA, and acylcarnitine in ischemic heart.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Carnitine; Constriction; Coronary Disease; Dogs; F | 1983 |
Protection of ischemic myocardium from metabolic products.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Circulation; Coronary Disease; Fatty Acids; Glucose; G | 1981 |
Electrophysiological and biochemical derangements in ischemic myocardium: interactions involving the cell membrane.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Cats; Cell Membrane; Coronary Disease; Electrophysiology; | 1981 |
On the mechanism of ischemia-induced mitochondrial dysfunction.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Dogs; Female; Lipid Metabolism; Male; Mitocho | 1982 |
Properties of carnitine incorporation in working swine hearts. Effects of coronary flow, ischemia, and excess fatty acids.
Topics: Acyl Coenzyme A; Animals; Biological Transport; Carnitine; Coronary Circulation; Coronary Disease; F | 1982 |
Reversal of ischemia-induced mitochondrial dysfunction after coronary reperfusion.
Topics: Acyl Coenzyme A; Adenosine Diphosphate; Animals; Carnitine; Coronary Circulation; Coronary Disease; | 1982 |
Structural, functional, and metabolic correlates in ischemic hearts: effects of substrates.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Glucose; Microscopy, Electron; Mitochondria, | 1981 |
Relationship between structure and fatty acid metabolism in mitochondria isolated from ischemic rat hearts.
Topics: Animals; Carnitine; Coenzyme A; Coronary Disease; Fatty Acids; Male; Mitochondria, Heart; Myocardium | 1981 |
Effects of carnitine isomers on fatty acid metabolism in ischemic swine hearts.
Topics: Animals; Cardiac Output; Carnitine; Coronary Disease; Fatty Acids; Fatty Acids, Nonesterified; Heart | 1981 |
Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Dogs; Energy Metaboli | 1981 |
Electrophysiological effects of amphiphiles on canine purkinje fibers. Implications for dysrhythmia secondary to ischemia.
Topics: Acidosis; Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Dogs; Electrophysiology; Fatty | 1981 |
Carnitine distribution in subepicardial and subendocardial regions in normal and ischemic dog hearts.
Topics: Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Dogs; Fatty Acids, Nonesterified; Myoc | 1981 |
[The anti-arrhythmic effect of L-carnitine in subjects with ischemic cardiopathy].
Topics: Adult; Aged; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Electrocardiography; Female; Humans; | 1981 |
Effects of carnitine and atractyloside on canine cardiac electrical activity.
Topics: Animals; Atractyloside; Carnitine; Coronary Disease; Dogs; Electrocardiography; Electrophysiology; F | 1981 |
Inhibition of myocardial lysophosphatidyl choline transacylase by palmitoyl carnitine: implications for arrhythmogenesis.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Acyltransferases; Animals; Arrhythmias, Cardiac; Carn | 1981 |
Acute myocardial ischaemia induces cardiac carnitine release in man.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Carnitine; Coronary Disease; Female; Hemodynamics; Humans; | 1997 |
[The effect of L-carnitine on ischemic heart disease: experimental results].
Topics: Carnitine; Coronary Disease; Fatty Acids; Glucose; Humans; Myocardial Ischemia | 1998 |
[Physiologic bases for the use of L-carnitine in cardiology].
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Disease Models, Animal; Fatty Acids; Glu | 1998 |
L-carnitine administration in coronary artery disease and cardiomyopathy.
Topics: Carnitine; Coronary Disease; Dietary Supplements; Heart; Humans; Myocardial Ischemia | 1998 |
Improved pacing tolerance of the ischemic human myocardium after administration of carnitine.
Topics: Carbon Dioxide; Cardiac Catheterization; Cardiac Pacing, Artificial; Carnitine; Coronary Disease; El | 1979 |
Coenzyme A and carnitine distribution in normal and ischemic hearts.
Topics: Animals; Carnitine; Citrate (si)-Synthase; Coenzyme A; Coronary Disease; Cytosol; Electron Transport | 1978 |
Palmitylcarnitine inhibition of the calcium pump in cardiac sarcoplasmic reticulum: a possible role in myocardial ischemia.
Topics: Animals; Biological Transport, Active; Calcium; Calcium-Transporting ATPases; Carnitine; Coronary Di | 1978 |
Some aspects of carnitine nutriture.
Topics: Animals; Carnitine; Catalysis; Coronary Disease; Diabetic Ketoacidosis; Fatty Acids; Humans; Lysine; | 1977 |
Role of carnitine in fatty acid metabolism of normal and ischemic myocardium.
Topics: Acetyl Coenzyme A; Acyl Coenzyme A; Angina Pectoris; Atractyloside; Biological Transport; Carnitine; | 1979 |
Effects of carnitine in ischemic and fatty acid supplemented swine hearts.
Topics: Adenosine Triphosphate; Animals; Aorta; Blood Pressure; Carnitine; Coronary Circulation; Coronary Di | 1979 |
Control of carnitine-related metabolism during myocardial ischemia.
Topics: Aerobiosis; Animals; Biological Transport; Carnitine; Carnitine O-Acetyltransferase; Cell Membrane P | 1979 |
The heart in diabetes mellitus.
Topics: Animals; Carnitine; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, | 1979 |
Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia.
Topics: Acetylcarnitine; Acyl Coenzyme A; Adenosine Triphosphate; Animals; Carnitine; Coenzyme A; Coronary D | 1978 |
Protection of the ischemic dog myocardium with carnitine.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Carnitine; Coronary Circulation; Coronary Disease; | 1978 |
Biochemical and morphological correlates of acute experimental myocardial ischemia in the dog. IV. Energy mechanisms during very early ischemia.
Topics: Acyl Coenzyme A; Acyltransferases; Animals; Carnitine; Carnitine O-Palmitoyltransferase; Citric Acid | 1979 |
Effects of ischemia on rat myocardial function and metabolism in diabetes.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus, Experimental; | 1979 |
Increased serum carnitine concentration in renal insufficiency.
Topics: Adult; Blood Urea Nitrogen; Carnitine; Coronary Disease; Humans; Kidney Diseases; Liver Cirrhosis; M | 1977 |
Role of adenine nucleotide translocase in metabolic change caused by ischemia.
Topics: Adenosine Diphosphate; Animals; Atractyloside; Carnitine; Cattle; Coenzyme A; Coronary Disease; Dogs | 1975 |
Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans.
Topics: Aged; Angina Pectoris; Blood Pressure; Carnitine; Coronary Disease; Female; Hemodynamics; Humans; In | 1992 |
Accumulation and excretion of long-chain acylcarnitine by rat hearts; studies with aminocarnitine.
Topics: Animals; Betaine; Carnitine; Carnitine O-Palmitoyltransferase; Coronary Disease; Disease Models, Ani | 1991 |
Protection of the reperfused heart by L-propionylcarnitine.
Topics: Animals; Blood Pressure; Carnitine; Coronary Circulation; Coronary Disease; Female; In Vitro Techniq | 1991 |
L-propionylcarnitine increases postischemic blood flow but does not affect recovery of energy charge.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium-Binding Proteins; Carnitine; Coronary Circulation; | 1991 |
Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function.
Topics: Adult; Carnitine; Coronary Disease; Female; Hemodynamics; Humans; Injections, Intravenous; Male; Mid | 1991 |
The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria.
Topics: Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Heart; Mitochondria, Heart; Myocardial | 1991 |
Protective effects of propionyl-L-carnitine during ischemia and reperfusion.
Topics: Acetylcarnitine; Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Hemodynamics; Male; Myocardi | 1991 |
Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium.
Topics: Animals; Carnitine; Coronary Disease; Dogs; Electrophysiology; Heart; Hypoxia; Membrane Potentials; | 1991 |
[Myocardial injury and phospholipases].
Topics: Acyl Coenzyme A; Animals; Carnitine; Cell Membrane; Cell Survival; Coronary Disease; Lipid Metabolis | 1990 |
Regulation of canine myocardial lysophospholipase.
Topics: Animals; Carnitine; Coronary Disease; Cytosol; Dogs; Female; Heart; Lysophospholipase; Male; Microso | 1990 |
Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases.
Topics: Adult; Biopsy; Cardiomyopathy, Dilated; Carnitine; Coronary Disease; Endocardium; Energy Metabolism; | 1990 |
Effect of D,L-carnitine on the response of the isolated heart of the rat to ischaemia and reperfusion: relation to mitochondrial function.
Topics: Animals; Carnitine; Coronary Disease; In Vitro Techniques; Male; Mitochondria, Heart; Mitochondrial | 1989 |
Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction.
Topics: Animals; Carnitine; Carnitine Acyltransferases; Coronary Disease; Diastole; Epoxy Compounds; Ethers, | 1989 |
Detrimental actions of endogenous fatty acids and their derivatives. A study of ischaemic mitochondrial injury.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Cytochromes; Electron | 1987 |
Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation.
Topics: Acyltransferases; Animals; Blood Flow Velocity; Carnitine; Carnitine Acyltransferases; Cats; Chromat | 1989 |
Coronary sinus lactate release as an index of myocardial anaerobiosis: effects of interventions.
Topics: Anaerobiosis; Carbohydrate Metabolism; Cardiac Pacing, Artificial; Cardiovascular Physiological Phen | 1986 |
[Carnitine in nutritional therapy].
Topics: Adenosine Triphosphate; Adult; Carnitine; Coronary Artery Bypass; Coronary Disease; Humans; Infant, | 1986 |
Carnitine-acylcarnitine translocase in ischemia: evidence for sulfhydryl modification.
Topics: Animals; Biological Transport; Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransfera | 1987 |
Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine.
Topics: Acyl Coenzyme A; Acyltransferases; Animals; Carnitine; Carnitine O-Palmitoyltransferase; Coronary Di | 1988 |
Effects of procainamide and disopyramide on long chain acyl carnitine and long chain acyl CoA concentrations in the ischemic heart.
Topics: Acyl Coenzyme A; Animals; Arrhythmias, Cardiac; Carnitine; Coronary Disease; Disopyramide; Dogs; Fat | 1988 |
[Carnitine metabolism--changes in the end stage of dilated cardiomyopathy and ischemic heart muscle disease].
Topics: Cardiomyopathy, Dilated; Carnitine; Coronary Disease; Heart Failure; Heart Transplantation; Humans; | 1987 |
The effects of propionylcarnitine taurine on cardiac performance in aerobic and ischemic myocardium.
Topics: Animals; Carnitine; Coronary Disease; Heart; Oxygen; Perfusion; Swine; Taurine | 1988 |
Carnitine metabolism. Role in acute ischemia and chronic myocardial disease.
Topics: Cardiomyopathies; Carnitine; Coronary Disease; Humans; Myocardium | 1987 |
Free radical-mediated damage during myocardial ischemia and reperfusion and protection by carnitine esters.
Topics: Animals; Carboxylic Acids; Carnitine; Coronary Circulation; Coronary Disease; Esters; Free Radicals; | 1987 |
Protection of the ischemic myocardium by propionylcarnitine taurine amide. Comparison with other carnitine derivatives.
Topics: Animals; Carnitine; Coronary Disease; Hemodynamics; Male; Myocardium; Rats; Rats, Inbred Strains; Ta | 1987 |
Acute diabetes mellitus does not impair survival rate in rats submitted to left coronary artery ligation.
Topics: Acute Disease; Animals; Blood Glucose; Carnitine; Coronary Disease; Coronary Vessels; Creatine Kinas | 1987 |
[Effect of taurine amide derivatives on post-ischemic myocardial recovery in the working heart model in the rat].
Topics: Animals; Blood Pressure; Carnitine; Coronary Circulation; Coronary Disease; Male; Models, Cardiovasc | 1986 |
[Carnitine in ischemic cardiomyopathy?].
Topics: Carnitine; Coronary Disease; Humans; Myocardium | 1987 |
Effects of L-carnitine on phospholipids in the ischemic myocardium.
Topics: Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Dogs; Drug Evaluation, Preclinical; Fe | 1987 |
Effects of the fatty acid blocking agents, oxfenicine and 4-bromocrotonic acid, on performance in aerobic and ischemic myocardium.
Topics: Aerobiosis; Animals; Butyrates; Carnitine; Carnitine O-Palmitoyltransferase; Coronary Disease; Croto | 1987 |
On the possible role of long chain fatty acylcarnitine accumulation in producing functional and calcium permeability changes in membranes during myocardial ischaemia.
Topics: Acetylcarnitine; Animals; Calcium; Carnitine; Cell Membrane Permeability; Coronary Disease; Myocardi | 1987 |
[Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level].
Topics: Animals; Carnitine; Cell Membrane; Coronary Disease; gamma-Butyrobetaine Dioxygenase; Male; Methylhy | 1987 |
The effects of ischaemia, lysophosphatidylcholine and palmitoylcarnitine on rat heart phospholipase A2 activity.
Topics: Animals; Carnitine; Coronary Disease; In Vitro Techniques; Lysophosphatidylcholines; Male; Myocardiu | 1987 |
Metabolic disturbances during acute lack of oxygen: a short overview.
Topics: Acyl Coenzyme A; Animals; Carnitine; Coronary Disease; Hypoxia; Myocardium | 1987 |
Reduction of ischemia-induced acyl carnitine accumulation by TDGA and its influence on lactate dehydrogenase release in diabetic rat hearts.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Carnitine; Coronary Disease; Diabetes Mellitus, Ex | 1986 |
Effects of L-carnitine in acute myocardial ischaemia.
Topics: Acute Disease; Animals; Arteries; Blood Pressure; Carnitine; Coronary Disease; Dogs; Fatty Acids, No | 1986 |
Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Blood Pressure; Cardiac Output; Carnitine; Coronar | 1986 |
Protection by acyl-carnitines and phenylmethylsulfonyl fluoride of rat heart subjected to ischemia and reperfusion.
Topics: Animals; Calcium; Carnitine; Cell Membrane; Coronary Disease; Cytosol; Glycogen Synthase; L-Lactate | 1985 |
Studies on experimental coronary insufficiency. Effect of L-carnitine on myocardial ischemia produced by sympathetic-nerve stimulation with high plasma fatty acids.
Topics: Animals; Carnitine; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Fat Emulsions | 1985 |
Effect of carnitine on myocardial function and metabolism following global ischemia.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Carnitine; Coronary Disease; Dogs; Fatty Acids; Hea | 1985 |
Effects of propranolol and diltiazem on carnitine derivatives and acyl CoA in ischemic myocardium.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Benzazepines; Carnitine; Cor | 1985 |
[Effects of carnitine (VBt) on the action potentials of rabbit ventricular muscle cells in situ during myocardial ischemia].
Topics: Action Potentials; Animals; Carnitine; Coronary Disease; Female; Heart Ventricles; Male; Microelectr | 1985 |
Effect of chronic myocardial ischemia on the activity of carnitine palmitylcoenzyme A transferase of isolated canine heart mitochondria.
Topics: Acyltransferases; Animals; Biological Transport, Active; Carnitine; Coenzyme A; Coronary Circulation | 1973 |